Márquez-Flores, Y.K.; Martínez-Galero, E.; Correa-Basurto, J.; Sixto-López, Y.; Villegas, I.; Rosillo, M.Á.; Cárdeno, A.; Alarcón-de-la-Lastra, C.
Daidzein and Equol: Ex Vivo and In Silico Approaches Targeting COX-2, iNOS, and the Canonical Inflammasome Signaling Pathway. Pharmaceuticals 2024, 17, 647.
https://doi.org/10.3390/ph17050647
AMA Style
Márquez-Flores YK, Martínez-Galero E, Correa-Basurto J, Sixto-López Y, Villegas I, Rosillo MÁ, Cárdeno A, Alarcón-de-la-Lastra C.
Daidzein and Equol: Ex Vivo and In Silico Approaches Targeting COX-2, iNOS, and the Canonical Inflammasome Signaling Pathway. Pharmaceuticals. 2024; 17(5):647.
https://doi.org/10.3390/ph17050647
Chicago/Turabian Style
Márquez-Flores, Yazmín K., Elizdath Martínez-Galero, José Correa-Basurto, Yudibeth Sixto-López, Isabel Villegas, María Á. Rosillo, Ana Cárdeno, and Catalina Alarcón-de-la-Lastra.
2024. "Daidzein and Equol: Ex Vivo and In Silico Approaches Targeting COX-2, iNOS, and the Canonical Inflammasome Signaling Pathway" Pharmaceuticals 17, no. 5: 647.
https://doi.org/10.3390/ph17050647
APA Style
Márquez-Flores, Y. K., Martínez-Galero, E., Correa-Basurto, J., Sixto-López, Y., Villegas, I., Rosillo, M. Á., Cárdeno, A., & Alarcón-de-la-Lastra, C.
(2024). Daidzein and Equol: Ex Vivo and In Silico Approaches Targeting COX-2, iNOS, and the Canonical Inflammasome Signaling Pathway. Pharmaceuticals, 17(5), 647.
https://doi.org/10.3390/ph17050647
